A Phase 1 Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors

Trial Profile

A Phase 1 Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Vantictumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors OncoMed Pharmaceuticals
  • Most Recent Events

    • 16 Sep 2016 Status changed to completed.
    • 28 Aug 2014 Status changed from suspended to recruiting (US FDA lifts the partial clinical hold).
    • 16 Jun 2014 According to an Oncomed media release, the company has voluntarily stopped enrollment and dosing in the phase 1 trials of vantictumab due to the incidence of bone-related adverse events.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top